MJardin Group, Inc. (“MJardin” or the”Business “) (CSE: MJAR), a pioneer in cannabis direction, today announced its initial medical cannabis research investment to finance two research on the advantages of cannabinoids on epilepsy and schizophrenia.
Starting in the first quarter of 2019, the research will be run at Salamanca, Spain for a duration of one year, in cooperation with Salamanca University and the Institute of Neuroscience of Castilla y León — two of the primary associations internationally for its scientific study from the nervous system and its ailments.
The study will focus on the effects of cannabidiol (CBD) on epilepsy and schizophrenia and will be directed by Dr. Dolores López, Ph.D. and Dr. Manuel S. Malmierca, Ph.D., M.D., both of whom are specialists in bronchial disorders and world famous for their study about the impact of cannabinoids on neurological Wellness
Christine Halef, BSc Pharm, RPh., SVP, Medical Strategy for MJardin, and Dr. Ashley Masri, ND, Medical Director for MJardin, will oversee the study for MJardin.
Halef based AtlantiCann Medical Inc. along with her history as a pharmacist gives a patient-focused outlook on providing alternative therapy options to states that commonly afflict communities around Canada.
Dr. Masri holds a postgraduate degree in Naturopathic Medicine from the Canadian College of Naturopathic Medicine and leverages her scientific background and expertise working with natural health products in patient care to coordinate MJardin’s medical research efforts.
“There’s a great deal of work to be performed from pre-clinical to clinical trials, to understand the medical advantages of cannabis on severe neurological disorders like epilepsy and schizophrenia,” explained Dr. Masri. “Spain is a recognized hub for clinical cannabis study and we are extremely happy to have the chance to collaborate with Salamanca University and the Institute of Neuroscience of Castilla y León to address this research gap and identify opportunities to enhance the lives of millions internationally.”
Dr. Dolores López, Research Full Professor in the University of Salamanca and also Director of this Audiomotor Illness’s Laboratory at the Neuroscience Institute of Castilla y Leon, remarked,”The cooperation agreement between MJardin along with the University of Salamanca opens a Terrific opportunity to transfer university knowledge to society, setting up the chance of new therapies for epilepsy and schizophrenia. This research project will offer advice on security, efficacy and dose of cannabidiol-based medications, and will let us improve the visibility of the research over the scientific community.”
MJardin will leverage the study to steer the attention of the organization’s medical cannabis branch, for example, growth of new products to deal with a variety of neurological conditions and ailments. Following conclusion of these research, MJardin expects engaging with the proper regulatory bodies to start testing and research of its products in Canada.
Since the leaders of MJardin’s medical cannabis branch, Halef and Dr. Masri will center on developing tactical R&D partnerships with reliable research associations to guarantee reliability and security of medicinal products to both doctors and patients.
“We’re pleased to supply monetary support for this crucial research whilst at the same time bringing and convening a worldwide coalition of specialists to advance medical cannabis research, deepen the business’s comprehension of medical cannabis, guarantee safe and efficient patient care, and develop MJardin’s medical branch,” additional Rishi Gautam, Chairman and Chief Executive Officer of MJardin.
Around MJardin Group
MJardin is a international cannabis management system with extensive knowledge in farming, processing, retail and distribution. For more than ten decades, MJardin has tasteful farming methodologies, developed state of the art centers and employed vertical integration for and on behalf of permit owners. As a well-capitalized business, MJardin continues to pursue strategic growth and M&A chances across international legal cannabis markets. MJardin is located in Denver Colorado, with offices in Toronto, Canada and Barcelona, Spain. To learn more, please see www.mjardin.com.